Scarica l'app Stockscreener
23.01
1.01%
0.2187
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PFE Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$22.79
Aprire:
$22.82
Volume 24 ore:
40.70M
Relative Volume:
0.84
Capitalizzazione di mercato:
$138.78B
Reddito:
$62.46B
Utile/perdita netta:
$7.88B
Rapporto P/E:
16.67
EPS:
1.38
Flusso di cassa netto:
$11.22B
1 W Prestazione:
-3.80%
1M Prestazione:
+5.40%
6M Prestazione:
-13.85%
1 anno Prestazione:
-18.57%
Intervallo 1D:
$22.51
$23.09
Intervallo di 1 settimana:
$22.51
$24.30
Portata 52W:
$20.91
$31.54
Pfizer Inc Stock (PFE) Company Profile
Nome
Pfizer Inc
Settore
Industria
Telefono
(212) 733-2323
Indirizzo
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Confronta PFE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
23.01 | 138.78B | 62.46B | 7.88B | 11.22B | 1.38 |
|
LLY
Lilly Eli Co
|
753.17 | 681.85B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
155.81 | 370.90B | 89.33B | 21.81B | 18.57B | 8.99 |
|
ABBV
Abbvie Inc
|
185.71 | 345.13B | 57.37B | 4.20B | 17.83B | 2.35 |
|
NVO
Novo Nordisk Adr
|
65.13 | 294.98B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
NVS
Novartis Ag Adr
|
110.26 | 224.15B | 53.22B | 12.86B | 14.85B | 6.39 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-25 | Ripresa | Citigroup | Neutral |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-08-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Downgrade | Argus | Buy → Hold |
| 2024-02-23 | Iniziato | Guggenheim | Buy |
| 2024-01-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-10-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-17 | Reiterato | JP Morgan | Neutral |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-06-29 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Downgrade | UBS | Buy → Neutral |
| 2023-01-17 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-12-13 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-04-06 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-20 | Reiterato | Cowen | Outperform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-13 | Aggiornamento | UBS | Neutral → Buy |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-05-06 | Downgrade | Mizuho | Buy → Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Aggiornamento | DZ Bank | Hold → Buy |
| 2020-12-16 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Ripresa | Goldman | Neutral |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-10-12 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-06-16 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-27 | Aggiornamento | Standpoint Research | Hold → Buy |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-07-30 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Ripresa | Morgan Stanley | Overweight |
| 2019-02-20 | Ripresa | Citigroup | Neutral |
| 2019-01-31 | Aggiornamento | Argus | Hold → Buy |
| 2019-01-31 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Downgrade | UBS | Buy → Neutral |
| 2018-12-11 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Mostra tutto
Pfizer Inc Borsa (PFE) Ultime notizie
Can Pfizer (PFE) Climb 25.14% to Reach the Level Wall Street Analysts Expect? - Yahoo Finance
The Mindfulness of Medicine Development: How Scientists Are Driving the Next Wave of Medical Innovations - Pfizer
Jim Cramer on Pfizer (PFE): “Trying Big Targets, but New Wins Still Elusive” - Insider Monkey
US FDA advisers to discuss COVID-19 vaccine recommendations on May 22 - marketscreener.com
Generic Oncology Drugs Market Size Estimated to Reach USD 30,998 Mn by 2034, Rising Global Cancer Cases Increase Demand for Affordable Treatments - GlobeNewswire Inc.
Pfizer (PFE) Awaits FDA Panel Review of Cancer Drug Combination - GuruFocus
Pfizer, J&J, Genentech drugs subject of FDA advisory panel meeting this month - Seeking Alpha
Ex-Dividend Reminder: American Electric Power, Pfizer and Tompkins Financial - Nasdaq
Pharma imports to US surged in March as drugmakers look to avoid tariffs - marketscreener.com
Trump Sets Pharma Tariffs Deadline. The Fallout for Lilly, Pfizer, Other Drugmakers. - Barron's
Pfizer (PFE) RSV Vaccine Recommendations Under Review - GuruFocus
Pfizer, GSK RSV shot recommendations under scrutiny from RFK Jr. aidereport - Seeking Alpha
PFE Stock Price: Pfizer Inc Named Top Dividend Stock as Insider Buying Surges, Yield Hits 7.21% - paginasiete.bo
Pfizer Has Unreasonable Whiff Of The Marlboro Man - Seeking Alpha
Pfizer Named Top Dividend Stock With Insider Buying and 7.21% Yield (PFE) - Nasdaq
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cerevel Therapeutics - TradingView
Here's Why We're Wary Of Buying Pfizer's (NYSE:PFE) For Its Upcoming Dividend - simplywall.st
Do These 3 Checks Before Buying Pfizer Inc. (NYSE:PFE) For Its Upcoming Dividend - Yahoo Finance
Recombinant Human Endostatin Market Top PlayersPfizer Inc., - openPR.com
Pfizer Stock Up 5% Following Q1 Results: Time To Buy, Sell Or Hold? - Barchart.com
Analyst recommendations: Amazon, PepsiCo, Linde, Pfizer, Crowdstrike Holdings... - marketscreener.com
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Sirolimus Market Is Booming Worldwide 2025-2032 | Pfizer Inc., Actiza, Zydus Cadila Healthcare Ltd. - openPR.com
Pfizer Stock Up 5% Following Q1 Results: Time to Buy, Sell or Hold? - Zacks Investment Research
Anti Suicide Drugs Market Detailed In New Research Report 2025 | - openPR.com
Is Pfizer Inc. (PFE) The Most Profitable Cheap Stock to Buy Now? - Insider Monkey
Is Pfizer Inc.'s (NYSE:PFE) Stock Price Struggling As A Result Of Its Mixed Financials? - Yahoo Finance
West Virginia counties, cities to receive Pfizer settlement checks - WBOY.com
Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com
Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (May 2025) - 24/7 Wall St.
Drug Discovery Market Is Booming So Rapidly 2025-2032Pfizer - openPR.com
Pfizer Inc (PFE-N) Stock Price and News - The Globe and Mail
Do Wall Street Analysts Like Pfizer Stock? - Nasdaq
Arvinas Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Zacks.com featured highlights Centene, Pediatrix Medical, Pfizer, StoneCo and Banco Santander - Nasdaq
Pfizer donates $250K to Oklahoma Tribal health clinics - The Journal Record
What's Next For Pfizer Stock After A Mixed Q1? - Nasdaq
Judge Keeps Pfizer Foe's COVID Vaccine Patent Case Alive - Law360
Pfizer CEO Tariff Uncertainty Hinders U.S. Investments - MSN
Pfizer CEO Albert Bourla Emphasizes National Security In US Drug Manufacturing - Benzinga
Pfizer (NYSE:PFE) Reports Q1 Earnings, Reaffirms 2025 Revenue Guidance at US$61-64 Billion - Yahoo Finance
Pfizer (PFE) Rating Upgraded: Signs of Stabilization Amid Strate - GuruFocus
Pfizer, BioNTech Fail to Void Alnylam’s Covid-Shot Patent Claims - Bloomberg Law News
Pfizer donates $750,000 to tribal health centers in Oklahoma - News On 6
Ibuprofen Drug Market Deep Research Report with Forecast by 2032 | Pfizer Inc., Johnson & Johnson, Bayer AG - openPR.com
Pfizer Inc. (NYSE:PFE) Q1 2025 Earnings Call Transcript - Insider Monkey
Is Pfizer Stock A Buy Or A Sell On Its Massive Savings Plan? - Investor's Business Daily
Fentanyl Drug Market Deep Research Report with Forecast by 2032 | - openPR.com
Pfizer Pulls Plug on Weight-Loss Pill Amid Health Concerns - CEO Today
Pfizer shifts to cost-cutting, new drug research after weight-loss bet fizzles - Crain's New York Business
Will Pfizer Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback? - Yahoo Finance
Pfizer Inc Azioni (PFE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):